Incyte Forecast, price target & analysts
Incyte Target price 2025 - Analyst rating & recommendation
Incyte Classifications & Recommendation:
Incyte Price Target
| Target Price | $83.64 |
| Price | $103.89 |
| Deviation |
19.49%
register free of charge
|
| Number of Estimates | 24 |
|
24 Analysts have issued a price target Incyte 2026 .
The average Incyte target price is $83.64.
This is
19.49%
register free of charge
$120.75
16.23%
register free of charge
$65.65
36.81%
register free of charge
|
|
| A rating was issued by 33 analysts: 15 Analysts recommend Incyte to buy, 17 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Incyte stock has an average upside potential 2026 of
19.49%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 4.24 | 5.06 |
| 14.76% | 19.33% | |
| EBITDA Margin | 3.19% | 33.79% |
| 82.52% | 959.68% | |
| Net Margin | 0.77% | 26.99% |
| 95.24% | 3,409.21% |
28 Analysts have issued a sales forecast Incyte 2025 . The average Incyte sales estimate is
This results in the following potential growth metrics:
10 Analysts have issued an Incyte EBITDA forecast 2025. The average Incyte EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
30 Incyte Analysts have issued a net profit forecast 2025. The average Incyte net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 0.15 | 6.97 |
| 94.34% | 4,546.67% | |
| P/E | 14.91 | |
| EV/Sales | 3.46 |
30 Analysts have issued a Incyte forecast for earnings per share. The average Incyte EPS is
This results in the following potential growth metrics and future valuations:
Current Incyte Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Piper Sandler |
Locked
➜
Locked
|
Locked | Nov 04 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Nov 03 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Oct 29 2025 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Oct 29 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Oct 29 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Oct 29 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Oct 09 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Nov 04 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Nov 03 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Oct 29 2025 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Oct 29 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Oct 29 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Oct 29 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Oct 09 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
